Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Radezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | CALML3 | P27482 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | SDHA | P31040 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radezolid SCHEMBL1036409 | 1.00 | MAOA (0.56) | MAOACALML3MAOBPTGS1SDHA | |
| Radezolid SCHEMBL3081908 | 0.99 | MAOA (0.55) | MAOACALML3MAOBPTGS1SDHA | |
| Radezolid SCHEMBL3081912 | 0.99 | MAOA (0.55) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL17749422 | 0.91 | CALML3 (0.46) | MAOACALML3MAOBF10 | |
| SCHEMBL17747987 | 0.91 | CALML3 (0.46) | MAOACALML3MAOBF10 | |
| SCHEMBL15445622 | 0.89 | CALML3 (0.49) | MAOACALML3MAOB | |
| SCHEMBL1393895 | 0.89 | MAOA (0.59) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL1394066 | 0.86 | CALML3 (0.62) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL14780780 | 0.86 | MAOA (0.56) | MAOACALML3MAOBPTGS1SDHA | |
| Radezolid SCHEMBL19611836 | 0.86 | MAOA (0.56) | MAOACALML3MAOBPTGS1SDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442526-B1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3442526-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Melinta Subsidiary Corp. (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017200979-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| US-9126991-B2 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2015-09-08 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | RPL27A, GRHPR, RAD52 | MAOA 3452/4885CALML3 2920/4885MAOB 2745/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | MAOA 379/4885CALML3 2223/4885MAOB 219/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885CALML3 4401/4885MAOB 1093/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885CALML3 4401/4885MAOB 1093/4885 |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | PROKR1, VIP, SI | MAOA 1794/4885CALML3 4339/4885MAOB 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.